Y
Yoshiya Horimoto
Researcher at Juntendo University
Publications - 91
Citations - 1095
Yoshiya Horimoto is an academic researcher from Juntendo University. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 16, co-authored 71 publications receiving 828 citations. Previous affiliations of Yoshiya Horimoto include Imperial College London.
Papers
More filters
Journal ArticleDOI
ATM and p53 regulate FOXM1 expression via E2F in breast cancer epirubicin treatment and resistance
Julie Millour,Natalia de Olano,Yoshiya Horimoto,Lara J. Monteiro,Julia K. Langer,Rosa Aligué,Nabil Hajji,Eric Lam +7 more
TL;DR: The data show that ATM and p53 coordinately regulate FOXM1 via E2F to modulate epirubicin response and resistance in breast cancer.
Journal ArticleDOI
Carcinoma-Associated Fibroblasts Are a Promising Therapeutic Target
TL;DR: The therapeutic feasibility of targeting tumour-promoting CAFs as well as disrupting heterotypic interactions with other cell types in tumours that may improve the efficacy of current anti-tumour therapies are discussed.
Journal ArticleDOI
Emerging roles of the tumor-associated stroma in promoting tumor metastasis
TL;DR: The stroma in human carcinomas consists of extracellular matrix and various types of non-carcinoma cells, mainly leukocytes, endothelial cells, fibroblasts, myofibroblast and bone marrow-derived progenitors, which actively supports tumor growth by stimulating neo-angiogenesis, as well as proliferation and invasion of apposed carcinoma cells.
Journal ArticleDOI
Combination of Cancer Stem Cell Markers CD44 and CD24 Is Superior to ALDH1 as a Prognostic Indicator in Breast Cancer Patients with Distant Metastases.
Yoshiya Horimoto,Atsushi Arakawa,Noriko Sasahara,Masahiko Tanabe,Sei Sai,Takanori Himuro,Mitsue Saito +6 more
TL;DR: The results raise the possibility of CD44+/24- being a good prognostic marker, one which would allow treatment effects and outcomes to be predicted in patients with recurrent breast cancer.
Journal ArticleDOI
Expression profiling and significance of VEGF-A, VEGFR2, VEGFR3 and related proteins in endometrial carcinoma.
Jayson Wang,Alexandra Taylor,Rania Showeil,Pritesh Trivedi,Yoshiya Horimoto,Izhar Bagwan,Lauren Ewington,Eric Lam,Mona El-Bahrawy,Mona El-Bahrawy +9 more
TL;DR: Evaluated VEGFR3 expression in tumors may provide prognostic data, and help identify patients who would best benefit from anti-angiogenic therapeutic agents, in the first report showing correlations between the expressions levels of the different receptors.